Advances in Intralesional Therapy for Locoregionally Advanced and Metastatic Melanoma: Five Years of Progress
Locoregionally advanced and metastatic melanoma are complex diagnoses with a variety of available treatment options. Intralesional therapy for melanoma has been under investigation for decades; however, it has advanced precipitously in recent years. In 2015, the Food and Drug Administration (FDA) ap...
Main Authors: | Danielle K. DePalo, Jonathan S. Zager |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-02-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/15/5/1404 |
Similar Items
-
Insights into the Molecular Mechanisms Behind Intralesional Immunotherapies for Advanced Melanoma
by: Dejan Vidovic, et al.
Published: (2020-05-01) -
Oncolytic viruses in melanoma
by: Camille Robinson, et al.
Published: (2022-02-01) -
Abscopal responses in patients with metastatic melanoma involving skin and subcutaneous tissues treated with intralesional IL2 plus BCG
by: Dejan Vidovic, et al.
Published: (2023-04-01) -
Advances in Targeting Cutaneous Melanoma
by: Dimitri Kasakovski, et al.
Published: (2021-04-01) -
Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy
by: Jian Xue, et al.
Published: (2021-08-01)